EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer

EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer

Abstract Background Cisplatin-based chemotherapy is recommended as the primary treatment for advanced bladder cancer (BC) with unresectable or metastatic disease. However, the benefits are limited due to the acquisition of drug resistance. The mechanisms of resistance remain unclear. Although there...

Full description

Bibliographic Details
Main Authors: Shunsuke Okamura, Hirofumi Yoshino, Kazuki Kuroshima, Masafumi Tsuruda, Yoichi Osako, Takashi Sakaguchi, Masaya Yonemori, Yasutoshi Yamada, Shuichi Tatarano, Masayuki Nakagawa, Hideki Enokida
Format: Article
Language:English
Published: BMC 2021-01-01
Series:BMC Cancer
Subjects:
Cisplatin resistance
Bladder cancer
EHHADH
miR-486-5p
Online Access:https://doi.org/10.1186/s12885-020-07717-0

Internet

https://doi.org/10.1186/s12885-020-07717-0

Similar Items